Dorzolamide

Evidence Level: L5

Predicted Indications: 7

Dorzolamide

Pharmacist Assessment Report

Dorzolamide: topical carbonic anhydrase inhibitor → hypotrichosis simplex of the scalp

One-Sentence Summary

Dorzolamide is a topical carbonic anhydrase inhibitor sold as an eye drop. The TxGNN model predicts it may be relevant to hypotrichosis simplex of the scalp, a genetic hair-loss disorder. This prediction has no clinical trials and no publications behind it, so it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	hypotrichosis simplex of the scalp
TxGNN Prediction Score	0.9995
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for dorzolamide is not currently available in the data compiled for this report. Pharmacology records show that dorzolamide acts on carbonic anhydrase isoforms CA1, CA7, CA12 and CA14. As an eye drop, it is applied locally and has low systemic exposure.

No plausible link was identified between carbonic anhydrase inhibition and hypotrichosis simplex of the scalp. This is an inherited disorder of the hair follicle. The high score is most likely a pattern-matching artifact of the model, with no clinical or literature support. In its current form, the prediction is a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Dorzolamide is marketed in India, and the licences reviewed are all valid. The five licences below are examples, and the full list may be partial. The licence records contain no approved-indication text.

Authorization Number	Product Name	Dosage Form	Approved Indication
63099	Dorz Eye Drop	Bottle of 5 ml eye drop	Not recorded in the local data
58413	Dorzox Eye Drop	Bottle of 5 ml eye drop	Not recorded in the local data
58797	Dorsun Eye Drop	Packet of 5 ml eye drop	Not recorded in the local data
73821	Endor Eye Drop	Packet of 5 ml eye drop	Not recorded in the local data
64940	Doreye Eye Drop	Bottle of 5 ml eye drop	Not recorded in the local data

All registered forms are ophthalmic (eye drops or ophthalmic solution). None is intended for scalp application.

Safety Considerations

Package-insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for these.

The data does flag the following conditions for caution. This is not label text:

Diabetes mellitus, diabetic ketoacidosis and hypoglycemia
Myasthenia gravis and other neuromuscular junction diseases
Hyperthyroidism, Graves disease and thyrotoxicosis
Atrioventricular block
Pulmonary emphysema and bronchial disease
Anaphylaxis

Any move to scalp or other non-ophthalmic use would need a new safety assessment, including the extent of systemic absorption.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score (0.9995) but no supporting trials or publications, and no plausible mechanism links carbonic anhydrase inhibition to this inherited hair disorder. The evidence level is L5.

To proceed, the following is needed:

Any preclinical or clinical study of dorzolamide in hair-follicle biology or hair-loss disorders
A defined mechanistic hypothesis connecting carbonic anhydrase isoforms to hair follicle function
Detailed mechanism-of-action data
Package-insert warnings and contraindications
A formulation and route assessment, since all current products are eye drops
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.